Cd73 pe cy7 clone ad2

Manufactured by BioLegend

Sourced in United Kingdom

CD73 (also known as ecto-5'-nucleotidase) is an enzyme that catalyzes the conversion of extracellular adenosine monophosphate (AMP) to adenosine. The CD73 PE-Cy7 Clone AD2 is a fluorescently labeled antibody that can be used to detect the expression of CD73 on cells.

Automatically generated - may contain errors

Lab products found in correlation

Facsaria 2, by BD (2 mentions) Kaluza 1, by Beckman Coulter (1 mentions) Facsdiva software, by Beckman Coulter (1 mentions)

Spelling variants of this product

CD73-PE (31 citations) CD73-PE-Cy7 (10 citations) CD73-PE (clone AD2), (2 citations)

2 protocols using cd73 pe cy7 clone ad2

Characterization of CD73 and PD-1 Expression on CD8+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Frozen PBMCs were thawed, briefly rested and then incubated with antibodies. Subpopulations of PBMCs were analysed using the following antibodies: CD3-V500, CD8-APC Clone BW135/80, PD-1-PE Clone PD1.3.1.3 (all from MiltenyiBiotecS.r.l.) and CD73 PE-Cy7 Clone AD2 (BioLegend UK Ltd). Samples Data were acquired using a FACSAria II (Becton–Dickinson, USA). Cell viability was assessed by 7-AAD staining. Dead cells were excluded by selecting only 7-AAD-negative cells. The population of lymphocytes was identified using a morphological gating on forward/side light scatters (FSC-A and SSC-A, respectively) and further gated by the expression of CD3 and CD8. The expression of CD73 and/or PD-1 were determined on the population of interest CD3+CD8+T cells (Additional file 1: Fig. S1). Data were analysed using Kaluza 1.2 software (Beckman Coulter).

Capone M., Fratangelo F., Giannarelli D., Sorrentino C., Turiello R., Zanotta S., Galati D., Madonna G., Tuffanelli M., Scarpato L., Grimaldi A.M., Esposito A., Azzaro R., Pinto A., Cavalcanti E., Pinto A., Morello S, & Ascierto P.A. (2020). Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients. Journal of Translational Medicine, 18, 121.

+ Open protocol

+ Expand

Analyzing PD-1 and CD73 on CD8+ T Cells in Melanoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

PBMCs from 47 melanoma patients were also collected at baseline and 9 months post-treatment. Subpopulations of PBMCs were analyzed using the following antibodies: CD3-V500, CD8-APC Clone BW135/80, PD-1-PE Clone PD1.3.1.3 (all from MiltenyiBiotecS.r.l.) and CD73 PE-Cy7 Clone AD2 (BioLegend). Samples data were acquired using a FACSAria II (Becton-Dickinson, USA). Cell viability was assessed by 7-AAD staining, and dead cells were excluded by selecting only 7-AAD-negative cells. The population of lymphocytes was identified using a morphological gating on forward/side light scatters (FSC-A and SSC-A, respectively) and further gated by the expression of CD3 and CD8. The expression of CD73 and/or PD-1 was determined on the population of interest (CD3 +CD8+T cells). Data were analyzed using FACS DIVA software (Beckman Coulter).

Mallardo D., Giannarelli D., Vitale M.G., Galati D., Trillò G., Esposito A., Isgrò M.A., D'Angelo G., Festino L., Vanella V., Trojaniello C., White A., De Cristofaro T., Bailey M., Pignata S., Caracò C., Petrillo A., Muto P., Maiolino P., Budillon A., Warren S., Cavalcanti E, & Ascierto P.A. (2022). Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis. Journal for Immunotherapy of Cancer, 10(11), e005132.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!